199 related articles for article (PubMed ID: 38093196)
1. Real-world clinical outcomes and treatment patterns in patients with MDD treated with vortioxetine: a retrospective study.
McDaniel BT; Cornet V; Carroll J; Chrones L; Chudzik J; Cochran J; Guha S; Lawrence DF; McCue M; Sarkey S; Lorenz B; Fawver J
BMC Psychiatry; 2023 Dec; 23(1):938. PubMed ID: 38093196
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of vortioxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder in routine clinical practice: A subgroup analysis of the RELIEVE study.
Almeida SS; Christensen MC; Simonsen K; Adair M
J Psychopharmacol; 2023 Mar; 37(3):279-288. PubMed ID: 36377523
[TBL] [Abstract][Full Text] [Related]
3. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study.
Chokka P; Bougie J; Proulx J; Tvistholm AH; Ettrup A
CNS Spectr; 2019 Dec; 24(6):616-627. PubMed ID: 30802419
[TBL] [Abstract][Full Text] [Related]
4. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
Fourrier C; Sampson E; Mills NT; Baune BT
Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
[TBL] [Abstract][Full Text] [Related]
5. A Taiwanese study on real-world evidence with vortioxetine in patients with major depression in Asia (TREVIDA).
Yang YK; Chen CS; Tsai CF; Chang CM; Lai TJ; Lee CT; Lin CC; Lan TH; Herr KJ
Curr Med Res Opin; 2021 Dec; 37(12):2163-2173. PubMed ID: 34515596
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
Mahableshwarkar AR; Jacobsen PL; Chen Y
Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
[TBL] [Abstract][Full Text] [Related]
7. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine.
Nierenberg AA; Loft H; Olsen CK
J Affect Disord; 2019 May; 250():35-42. PubMed ID: 30826492
[TBL] [Abstract][Full Text] [Related]
8. Effect of vortioxetine in subjects with major depressive and alcohol use disorders: a 6-month retrospective analysis.
Di Nicola M; Pepe M; Panaccione I; Moccia L; Dattoli L; Molinaro M; Sani G; Janiri L; McIntyre RS
CNS Spectr; 2022 Feb; 27(1):73-81. PubMed ID: 32772956
[TBL] [Abstract][Full Text] [Related]
9. Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD).
Chokka P; Bougie J; Rampakakis E; Proulx J
CNS Spectr; 2019 Jun; 24(3):338-347. PubMed ID: 29792585
[TBL] [Abstract][Full Text] [Related]
10. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
Jacobsen PL; Mahableshwarkar AR; Chen Y; Chrones L; Clayton AH
J Sex Med; 2015 Oct; 12(10):2036-48. PubMed ID: 26331383
[TBL] [Abstract][Full Text] [Related]
11. Results of a real-world study on vortioxetine in patients with major depressive disorder in South East Asia (REVIDA).
Chin CN; Zain A; Hemrungrojn S; Ung EK; Kwansanit P; Au Yong KC; Chong MSW; Inpa C; Yen TH; Yeoh BBD; Tay LK; Bernardo C; Lim LC; Yap CH; Fones C; Nayak A; Nelleman L
Curr Med Res Opin; 2018 Nov; 34(11):1975-1984. PubMed ID: 29768955
[TBL] [Abstract][Full Text] [Related]
12. A comparison of real-world effectiveness of vortioxetine along the treatment algorithm for major depressive disorder.
Bose R; Hamdani SU; Minhas FA; Herr KJ
Curr Med Res Opin; 2022 May; 38(5):661-671. PubMed ID: 35049384
[TBL] [Abstract][Full Text] [Related]
13. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram.
Levada OA; Troyan AS
J Affect Disord; 2019 May; 250():114-122. PubMed ID: 30852363
[TBL] [Abstract][Full Text] [Related]
14. Canadian economic impact of improved workplace productivity in patients with major depressive disorder treated with vortioxetine.
Lachaine J; Beauchemin C; Bibeau J; Patenaude J; Chokka P; Proulx J; Bougie J
CNS Spectr; 2020 Jun; 25(3):372-379. PubMed ID: 31120009
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of vortioxetine in patients with major depressive disorder and early-stage dementia: The MEMORY study.
Christensen MC; Schmidt SN; Grande I
J Affect Disord; 2023 Oct; 338():423-431. PubMed ID: 37315590
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Vortioxetine in Working Patients with Major Depressive Disorder in China: A Subgroup Analysis of the RELIEVE China Study.
Wang G; Si T; Rieckmann A; Ma J; Christensen MC
Neuropsychiatr Dis Treat; 2024; 20():1211-1223. PubMed ID: 38863483
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of Vortioxetine in Patients with Major Depressive Disorder in Real-World Clinical Practice: French Cohort Results from the Global RELIEVE Study.
Polosan M; Rabbani M; Christensen MC; Simonsen K; Ren H
Neuropsychiatr Dis Treat; 2022; 18():1963-1974. PubMed ID: 36068858
[TBL] [Abstract][Full Text] [Related]
19. Design of a real-world, prospective, longitudinal, observational study to compare vortioxetine with other standard of care antidepressant treatments in patients with major depressive disorder: a PatientsLikeMe survey.
Raveendran S; Singh D; Burke MC; McAuliffe-Fogarty AH; Parikh SV; McIntyre RS; Roy A; Martin M; Chrones L; Opler MGA; Blair C; McCue M
BMC Psychiatry; 2023 Jun; 23(1):464. PubMed ID: 37365543
[TBL] [Abstract][Full Text] [Related]
20. Adherence and persistence among patients with major depressive disorder enrolled in the vortioxetine tAccess Patient Support Program.
Lawrence DF; Manjelievskaia J; Chrones L; McCue M; Touya M
Curr Med Res Opin; 2021 Aug; 37(8):1385-1392. PubMed ID: 33904815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
